MERTK and rheumatoid arthritis: Interestingly, etanercept and adalimumab were found to promote the polarization of CD14pos monocyte-derived M-CSF-polarized macrophages from RA patients by decreasing inflammatory surface markers (CD40, CD80) and enhancing alternative markers (CD16, CD163, and MerTK) [40].